Literature DB >> 14638868

Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.

Emma Shtivelman1.   

Abstract

The role of the protein kinase B (PKB/Akt) in the regulation of cell survival and proliferation is well established. PKB is a key effector in the phosphatidylinositol 3-kinase pathway and plays a role in the initiation of S phase and in the G(2)-M transition. I report here that activated PKB shortens the G(2) arrest induced by DNA damage and promotes early entry into mitosis. Activated PKB supports high levels of expression and activity of the polo-like kinase 1 (Plk1) after DNA damage as cells accumulate in G(2). The checkpoint protein CHFR implicated in degradation of Plk1 is involved in the regulation of Plk1 by PKB. PKB phosphorylates CHFR in vitro and in vivo. Expression of a mutant form of CHFR that cannot be phosphorylated by PKB results in reduction of levels of Plk1 and inhibition of mitotic entry under normal conditions and after DNA damage. Results of this study support a model in which PKB facilitates mitotic resolution of DNA damage-induced G(2) arrest by inhibiting the checkpoint function of CHFR. The deregulated activation of PKB that occurs frequently in tumors might inhibit CHFR activity after DNA damage and therefore promote Plk1 accumulation leading to the disruption of the DNA damage checkpoint.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638868

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  20 in total

Review 1.  Ubiquitin and SUMO systems in the regulation of mitotic checkpoints.

Authors:  Gustavo J Gutierrez; Ze'ev Ronai
Journal:  Trends Biochem Sci       Date:  2006-05-02       Impact factor: 13.807

2.  Role of IGF-1 receptor in radiation response.

Authors:  Almudena Valenciano; Luis Alberto Henríquez-Hernández; Mercedes Moreno; Marta Lloret; Pedro Carlos Lara
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

3.  The auto-ubiquitylation of E3 ubiquitin-protein ligase Chfr at G2 phase is required for accumulation of polo-like kinase 1 and mitotic entry in mammalian cells.

Authors:  Jo-Sun Kim; Yong-Yea Park; Sun-Yi Park; Hyeseon Cho; Dongmin Kang; Hyeseong Cho
Journal:  J Biol Chem       Date:  2011-07-15       Impact factor: 5.157

Review 4.  CHFR: a key checkpoint component implicated in a wide range of cancers.

Authors:  Sheru Sanbhnani; Foong May Yeong
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

Review 5.  Spatiotemporal regulation of the Dma1-mediated mitotic checkpoint coordinates mitosis with cytokinesis.

Authors:  Sierra N Cullati; Kathleen L Gould
Journal:  Curr Genet       Date:  2019-01-02       Impact factor: 3.886

6.  Yeast Chfr homologs retard cell cycle at G1 and G2/M via Ubc4 and Ubc13/Mms2-dependent ubiquitination.

Authors:  Greta L Loring; Kathryn C Christensen; Scott A Gerber; Charles Brenner
Journal:  Cell Cycle       Date:  2007-10-02       Impact factor: 4.534

7.  Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression.

Authors:  Xuesong Liu; Yan Shi; Keith W Woods; Paul Hessler; Paul Kroeger; Julie Wilsbacher; Jieyi Wang; Jean Y Wang; Chunying Li; Qun Li; Saul H Rosenberg; Vincent L Giranda; Yan Luo
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

8.  Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.

Authors:  Zheng Fu; Kevin Regan; Lizhi Zhang; Michael H Muders; Stephen N Thibodeau; Amy French; Yanhong Wu; Scott H Kaufmann; Wilma L Lingle; Junjie Chen; Donald J Tindall
Journal:  J Clin Invest       Date:  2009-08-17       Impact factor: 14.808

Review 9.  FHA-RING ubiquitin ligases in cell division cycle control.

Authors:  L Brooks; E G Heimsath; G L Loring; C Brenner
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

Review 10.  Physiological and oncogenic Aurora-A pathway.

Authors:  Toshiaki Saeki; Mutsuko Ouchi; Toru Ouchi
Journal:  Int J Biol Sci       Date:  2009-11-26       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.